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OBJECTIVES The aim of the study was to evaluate the effects of intravenous (IV) flecainide on defibrillation
energy requirements in patients treated with low-energy internal atrial cardioversion.
BACKGROUND Internal cardioversion of atrial fibrillation is becoming a more widely accepted therapy for
acute episode termination and for implantable atrial defibrillators.
METHODS Twenty-four patients with atrial fibrillation (19 persistent, 5 paroxysmal) underwent elective
transvenous cardioversion according to a step-up protocol. After successful conversion in a
drug-free state, atrial fibrillation was induced by atrial pacing; IV flecainide (2 mg/kg) was
administered and a second threshold was determined. In patients in whom cardioversion in
a drug-free state failed notwithstanding a 400- to 550-V shock, a threshold determination
was attempted after flecainide.
RESULTS Chronic persistent atrial fibrillation was converted in 13/19 (68%) patients at baseline and in
16/19 (84%) patients after flecainide. Paroxysmal atrial fibrillation was successfully cardio-
verted in all the patients. A favorable effect of flecainide was observed either in chronic
persistent atrial fibrillation (13 patients) or in paroxysmal atrial fibrillation (5 patients) with
significant reductions in energy requirements for effective defibrillation (persistent atrial
fibrillation: 4.42 6 1.37 to 3.50 6 1.51 J, p , 0.005; paroxysmal atrial fibrillation: 1.68 6
0.29 to 0.84 6 0.26 J, p , 0.01). In 14 patients not requiring sedation, the favorable effects
of flecainide on defibrillation threshold resulted in a significant reduction in the scores of
shock-induced discomfort (3.71 6 0.83 vs. 4.29 6 0.61, p , 0.005). No ventricular
proarrhythmia was observed for any shock.
CONCLUSIONS Intravenous flecainide reduces atrial defibrillation threshold in patients treated with low-
energy internal atrial cardioversion. This reduction in threshold results in lower shock-
induced discomfort. Additionally, flecainide may increase the procedure success rate in
patients with chronic persistent atrial fibrillation. (J Am Coll Cardiol 1999;33:333–41) ©
1999 by the American College of Cardiology
Internal cardioversion of atrial fibrillation can be performed
at relatively low energies by delivering biphasic shocks
through transvenous catheters positioned in right atrium
and coronary sinus or left pulmonary artery (1–3). This
procedure has been studied in animal models (4,5), and
more recently both its efficacy and safety have been evalu-
ated in patients with paroxysmal or chronic atrial fibrillation
(1–3,6,7).
Antiarrhythmic drugs may influence defibrillation energy
requirements for atrial cardioversion, although conflicting
reports of drug effect on conventional transthoracic cardio-
version have been published (8–13). More recently the
effects of sotalol have been evaluated in patients treated with
transvenous low-energy internal atrial cardioversion (14).
The aim of this study was to investigate the effects of
intravenous (IV) flecainide on defibrillation energy require-
ments in a series of patients with atrial fibrillation treated by
elective internal atrial cardioversion, evaluating the potential
clinical usefulness of this drug and its safety profile.
METHODS
Patients enrolled in this study fulfilled the following selec-
tion criteria, according to a recent classification of atrial
fibrillation (15): 1) patients with a history of chronic
paroxysmal atrial fibrillation, with arrhythmia episodes last-
ing more than 3 days, undergoing electrophysiologic study
for atrial fibrillation mechanism evaluation; 2) patients with
a history of chronic atrial fibrillation in the persistent form
where the arrhythmia persisted for at least 1 week. Arrhyth-
mia onset was documented by electrocardiographic (ECG)
recordings or by an abrupt onset of palpitations with
subsequent ECG evidence of atrial fibrillation.
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Patients were excluded for the following criteria: age .80
years; heart failure, New York Heart Association (NYHA)
class IV; left ventricular ejection fraction ,40%; mean
ventricular rate during atrial fibrillation ,45 beats/min;
recent (,6 months) myocardial infarction; unstable angina
pectoris; ECG evidence (presence or past) of ventricular
preexcitation or complete bundle branch block; previous
ECG evidence of second or third degree atrioventricular
block or bifascicular block; sick sinus syndrome; hypokale-
mia (potassium ,3.5 mEq/L); severe renal or hepatic failure
and severe hypoxia (partial pressure of oxygen
,55 mm Hg). The study protocol was approved by our local
ethics committee and all patients gave informed consent.
The anticoagulation guidelines of the American College of
Chest Physicians (16) were followed. Therefore, patients
with atrial fibrillation lasting more than 72 h were enrolled
into the study only if they received oral warfarin treatment
for at least 3 to 4 weeks with an INR (international
normalized ratio) in the therapeutic range (2.0 to 3.5). The
procedure was performed after an antiarrhythmic drugs
(including digoxin) washout period of at least 5 half-lives.
Electrophysiological study and atrial cardioversion. In
the electrophysiology laboratory, catheters were positioned
under fluoroscopy. Two identical 6F decapolar catheters
(Electro Catheter), each with a total electrode surface area
of 2.83 cm2 and an electrode length of 6 cm, were inserted
through left subclavian vein puncture and right femoral vein
puncture for positioning into the coronary sinus and the
anterolateral right atrial wall, respectively (Fig. 1). When
access into the coronary sinus was unsuccessful after several
attempts, the catheter was alternatively positioned in the left
pulmonary artery (1). Additionally, a 6F quadripolar cath-
eter was advanced from a femoral vein and positioned in the
right ventricular apex to provide accurate R-wave syncroni-
zation and back-up ventricular pacing, if required. The
decapolar defibrillation catheters were connected to an
external atrial defibrillator (right atrium negative, left atrium
positive). In 11 patients a Telectronics 4510 defibrillator
(capacitor 120 mF) and in 13 patients a XAD defibrillator
(InControl) (capacitor 90 mF) were employed. With both
devices, biphasic truncated exponential shocks were deliv-
ered with two phases of 3-ms duration each. Leading-edge
voltage was programmed between 20 and 400 V (up to 550
V, if necessary, when using the Telectronics device). For
safety reasons, shocks were delivered only after RR intervals
between 500 and 1000 ms (5).
After delivery of a test shock of 20 to 50 V to verify
proper R-wave syncronization, shocks were delivered in the
following sequence, with a 1-min interval between shocks:
50 V, 100 V, 120 V, 150 V, 180 V, and then further
increases by steps of 40 V in patients with paroxysmal atrial
fibrillation; 100 V, 150 V, 180 V, and then further increases
by steps of 40 V in patients with chronic persistent atrial
fibrillation up to 400 V, and then 450 V, 500 V and 550 V.
We considered a shock successful if stable sinus rhythm
was restored within 3 s of a shock. In this case the sequence
of shocks was terminated. Cardiac rhythm was continuously
monitored during the procedure and surface ECG was
recorded to paper during shock delivery.
Premedication or sedation was not routinely administered
before or during the procedure; rather, shock-induced
discomfort was monitored after each shock, and sedation, or
general anesthesia, was administered at patient’s request.
After each shock patients were requested to report the
tolerability of shock-induced discomfort (scale: 1 5 shock
not felt; 2 5 shock felt, no discomfort; 3 5 mild discomfort;
4 5 moderate discomfort; 5 5 severe discomfort) and were
given the option of requesting sedation, or anesthesia, if
discomfort was intolerable.
Atrial cardioversion retesting after flecainide. Flecainide
acetate was infused intravenously during 15 min (dose of
2 mg/kg), under ECG monitoring. Cuff blood pressure was
checked every 5 min. In patients with successful cardiover-
sion at baseline, atrial fibrillation was reinduced by atrial
pacing, intravenous (IV) flecainide was administered and a
new series of shocks was delivered 30 min after infusion end
(shock delivery began with a leading-edge voltage 80 V less
than the previous effective shock voltage). In patients with
unsuccessful cardioversion at baseline, after shocks at max-
imal output had been tested twice, IV flecainide was
administered and a new series of shocks was delivered after
30 min. Figure 2 shows the protocol employed in the series
of patients not submitted to atrial cardioversion retesting in
drug-free conditions.
Atrial cardioversion retesting in drug-free conditions. In
10 consecutive patients (the first 2 with paroxysmal and the
first 8 with chronic persistent atrial fibrillation), following
atrial cardioversion of baseline atrial fibrillation, atrial fibril-
lation was reinduced by atrial pacing (atrial extrastimuli or
atrial bursts), and after induction of an atrial fibrillation
Figure 1. Catheter placement at fluoroscopy (anteroposterior
view) with a quadripolar catheter at right ventricular apex, a
decapolar catheter in coronary sinus, and a decapolar catheter in
right lateral atrial wall.
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lasting 30 min a new series of shocks was tested for assessing
the reproducibility of effective shocks in a drug-free condi-
tion. In the second series of shocks the same protocol
employed after flecainide administration was used (shock
delivery began with a leading-edge voltage 80 V less than
the previous effective shock voltage). The same patients
were subsequently submitted to flecainide administration
and atrial cardioversion retesting as the other patients.
Figure 3 shows the protocol employed in this series of 10
patients, submitted to atrial cardioversion retesting in drug-
free conditions.
Analysis of ECG and electrophysiological changes. Dur-
ing atrial fibrillation, intracardiac electrograms were re-
corded at 100 mm/s (Mingograph 7, Siemens Elema) from
high right atrium (HRA) and coronary sinus (CS) with a
filter setting between 30 and 500 Hz and the mean value of
100 consecutive FF intervals (mean FF) was calculated
before atrial cardioversion, at baseline and after flecainide
administration (17). In the same samples mean RR intervals
were calculated. The QRS intervals width was measured in
five consecutive intervals and averaged before atrial cardio-
version, at baseline and after flecainide administration,
immediately before delivery of shocks.
Serum flecainide concentrations. Blood samples of 5 ml
were taken 15 and 30 min after the end of flecainide
infusion. Serum flecainide concentrations were determined
by fluorescence polarization immunoassay (18). The normal
range of flecainide concentrations is between 200 and 1000
ng/ml (19).
Statistical analysis. Continuous variables were compared
using Student t test for paired data; discrete variables were
compared using chi-square analysis of contingency tables.
Statistical significance was achieved at p , 0.05. Data on
patients submitted to cardioversion at baseline, after rein-
duction in drug-free conditions, and after flecainide were
analyzed by one-way analysis of variance (ANOVA) and
then by Bonferroni t test.
RESULTS
Patients. Overall, 24 patients entered the study: 5 patients
had paroxysmal atrial fibrillation, and sustained atrial fibril-
lation was induced during the electrophysiological study by
atrial pacing (1 to 3 extrastimuli or atrial bursts) and 19
patients had chronic persistent atrial fibrillation (mean
arrhythmia duration 8.5 6 9.9 months, range 3 to 48).
Patient characteristics (clinical and demographic variables)
are reported in Table 1.
Efficacy of atrial cardioversion. Overall successful cardio-
version was obtained at baseline in 18 patients (75%): in all
5 patients with paroxysmal atrial fibrillation and in 13 of the
patients with chronic persistent atrial fibrillation (68%). The
effects of IV flecainide were tested on a reinduced atrial
fibrillation in 15 patients (10 with chronic and 5 with
paroxysmal atrial fibrillation), on a spontaneous early recur-
rence of atrial fibrillation in 3 patients (all with previous
persistent atrial fibrillation) and on the same arrhythmia, for
unsuccessful conversion at baseline, in 6 patients.
Following flecainide, successful cardioversion was ob-
tained in 21 patients (88%); all the patients successfully
converted at baseline were also converted after flecainide,
whereas 3 out of 6 nonresponder patients with persistent
atrial fibrillation were successfully converted to sinus rhythm
only after flecainide. Shocks were delivered between right
atrial and coronary sinus electrodes in 22 patients; in 2
patients, shocks were delivered between right atrium and
left pulmonary artery. In these two patients successful
cardioversion was obtained both at baseline (leading-edge
voltage 340 and 260 V, respectively) and after flecainide
(leading-edge voltage 340 and 220 V, respectively). Overall,
183 shocks were delivered at baseline and 65 after flecainide
(mean 7.6 6 1.7 and 2.7 6 1.1 shocks per patient,
respectively).
Effects of flecainide on defibrillation energy require-
ments. In the 18 patients with successful cardioversion at
baseline, in drug-free conditions (13 with persistent and 5
with paroxysmal atrial fibrillation), the mean leading-edge
voltage of successful shocks was 283 6 72 V (range 150 to
Figure 2. Study design: Flow chart of the study protocol in
patients with paroxysmal atrial fibrillation (PAF) or chronic
persistent atrial fibrillation (CAF) not submitted to atrial cardio-
version retesting in a drug-free condition. AF 5 atrial fibrillation.
Figure 3. Study design: Flow chart of the study protocol in
patients with paroxysmal atrial fibrillation (PAF) or chronic
persistent atrial fibrillation (CAF) submitted to atrial cardioversion
retesting in a drug-free condition. AF 5 atrial fibrillation.
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400 V), mean delivered energy was 3.66 6 1.71 J (range 1.2
to 6.7 J) and mean shock impedence was 49 6 6 ohms
(range 36 to 63 ohms). In the same patients the mean
leading-edge voltage of successful shocks after flecainide
administration was 241 6 86 V (range 100 to 400 V) (p ,
0.001 vs. baseline), mean delivered energy was 2.76 6 1.77
J (range 0.6 to 6.3 J) (p , 0.001 vs. baseline) and mean
shock impedence was 50 6 6 (range 36 to 63). In Figure 4,
individual values of voltage and corresponding energies at
baseline and after flecainide are shown. In only one patient
was an increase observed in voltage and energy of successful
shock following flecainide infusion.
In the 13 patients with persistent atrial fibrillation, shocks
delivered after flecainide resulted successful at lower voltages
(284 6 54 vs. 321 6 38 V, p , 0.005) and lower energies
compared to baseline cardioversion (3.50 6 1.51 vs. 4.42 6
1.37 J, p , 0.005). Even in the subgroup of five patients
with paroxysmal atrial fibrillation, shocks delivered after
flecainide resulted successful at lower voltages (130 6 34 vs.
184 6 27 V, p , 0.005) and lower energies compared to
baseline cardioversion (0.84 6 0.26 vs. 1.68 6 0.29 J, p ,
0.01). In the three patients who resulted to be nonre-
sponders at baseline (lack of cardioversion at 400 V), who
were successfully converted to sinus rhythm only after
flecainide, leading-edge voltage was 400 V for successful
shocks and 400 V for previous ineffective shocks at baseline,
and delivered energy was 6.00 6 0.17 J for successful shocks
and 6.10 6 0.10 J for previous ineffective shocks at baseline.
Sedation was required in six patients (25%) at baseline
and after flecainide administration. In the other 18 patients
sedation was not required at baseline nor after flecainide. In
patients not requiring sedation and with successful conver-
sion either at baseline and after flecainide (14 patients), the
reduction in leading-edge voltage and delivered energy of
effective shocks obtained after flecainide (278 6 74 to
235 6 91 V, p , 0.001 and 3.69 6 1.83 to 2.76 6 1.94 J,
p , 0.002) was associated with a significant reduction in
reported subjective score for shock-induced discomfort
(4.29 6 0.61 to 3.71 6 0.83, p , 0.005).
Reproducibility of effective shocks and effects of flecain-
ide. Data concerning effective shocks in the group of 10
patients (2 with paroxysmal atrial fibrillation, 8 with chronic
persistent atrial fibrillation) submitted to atrial cardioversion
at baseline, after atrial fibrillation reinduction in a drug-free
condition, and after flecainide are reported in Table 2. After
Table 1. Patient Population
Pt.
Number
Age
(years) Gender
Underlying
HD
AF
Duration
(months)
LA
Diameter
(mm) LV EF (%)
1 71 M Valvular HD — 50 57
2 69 F Hypertension — 44 62
3 58 M Hypertension — 41 57
4 49 M No HD — 42 65
5 42 M No HD — 36 67
6 65 F Valvular HD 5 45 65
7 62 F Hypertension 12 51 75
8 31 M No HD 3 44 55
9 73 F Hypertension 3 43 84
10 56 M Hypertension 8 38 58
11 68 F Hypertension 7 44 53
12 57 F Valvular HD 6 43 69
13 58 F DCM 48 44 69
14 69 F Hypertension 4 45 50
15 60 M Hypertension 6 58 73
16 75 F No HD 4 43 65
17 69 F Valvular HD 3 60 54
18 63 F CAD 8 42 71
19 71 M DCM 3 60 53
20 53 M Valvular HD 12 46 65
21 36 M DCM 9 49 56
22 63 F Hypertension 7 56 75
23 56 F Valvular HD 8 50 46
24 55 F Valvular HD 7 50 61
Mean 59 8.5 46.8 62.7
DS 11 9.9 6.4 9.2
Median 61 7 44.5 63.5
AF 5 atrial fibrillation; HD 5 heart disease; LA 5 left atrium; LV EF 5 left ventricular ejection fraction; CAD 5 coronary
artery disease; DCM 5 dilated cardiomyopathy.
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flecainide, conversion to sinus rhythm was obtained at
significantly lower leading-edge voltage and delivered en-
ergy compared to baseline, while no statistically significant
differences were found in these parameters between baseline
cardioversion and repeated cardioversion in a drug-free state
(Table 2).
Electrocardiographic and electrophysiological changes.
The effects of flecainide on mean FF intervals, mean RR
and QRS width are shown in Table 3. After flecainide,
mean FF intervals lengthened significantly either in high
right atrium (HRA) or coronary sinus (CS) (Fig. 5) and the
average change was 156.5% in HRA (range 12% to 100%)
and 158.5% in CS (range 22% to 91%).
The sinus pause at sinus rhythm resumption was 994 6
432 ms in basal conditions (18 patients) and 1452 6 810 ms
after flecainide (21 patients). In the 18 patients with
successful cardioversion either at baseline or after flecainide,
a significant lengthening of sinus pause at sinus rhythm
resumption was observed (Table 3).
Serum flecainide concentrations. Mean serum flecainide
concentrations were 1335 6 550 (range 500 to 2000) ng/ml
after 15 min and 455 6 177 (range 250 to 800) ng/ml
30 min after IV infusion.
Adverse effects. No ventricular arrhythmia was observed
after atrial cardioversion, either at baseline or after flecain-
ide. Transient bradycardia requiring support ventricular
pacing was observed in two patients. In no patient, pauses
.3 s were observed at sinus rhythm resumption, at baseline
cardioversion or after flecainide. Two patients had transient,
asymptomatic hypotension after flecainide infusion, and one
patient reported transient dizziness and lightheadedness in
absence of rhythm abnormalities.
DISCUSSION
This is the first study showing that IV flecainide may reduce
energy requirements in transvenous low-energy atrial car-
dioversion, without significant adverse effects. This reduc-
tion in defibrillation requirements may be associated with
Figure 4. Leading-edge voltage (top) and delivered energy (bottom)
for effective shocks in patients with paroxysmal or persistent atrial
fibrillation (AF) at baseline and after flecainide administration.
Table 2. Data on Effective Shocks in the Group of 10 Patients Submitted to Atrial
Cardioversion at Baseline, After Atrial Fibrillation Reinduction in a Drug-Free Condition and
After Flecainide
Pt.
Number
Leading-Edge Voltage (volts) Delivered Energy (joules)
Baseline
AF
Reinduced
AF
After
Flecainide
Baseline
AF
Reinduced
AF
After
Flecainide
1 120 140 100 0.90 1.10 0.60
2 180 140 100 1.90 1.10 0.60
6 340 300 300 6.70 5.10 5.00
7 260 260 220 2.60 2.60 1.80
8 340 300 300 6.70 5.10 5.00
9 280 320 320 2.90 3.80 3.80
10 300 300 220 3.40 3.40 1.80
11 300 240 220 3.50 2.20 1.90
12 300 300 300 3.20 3.20 3.20
13 300 340 260 3.40 4.50 2.60
Mean 272 264 234*† 3.52 3.21 2.68*
SD 70 71 80 1.86 1.47 1.60
*p , 0.05 vs. baseline AF. †p , 0.05 vs. reinduced AF.
AF 5 atrial fibrillation.
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either an increase in defibrillation efficacy or patient toler-
ance or both.
Preliminary data showed reduction in defibrillating ener-
gies with IV sotalol in humans (14), a finding not confirmed
in another animal study (20), and with IV procainamide in
animals (20). No significant changes in atrial defibrillation
threshold have been reported for flecainide in the canine
sterile pericarditis model (21). No data are available in the
literature on the effects of a class 1C drug administered
during internal low-energy cardioversion of atrial fibrillation
in humans, despite the fact that flecainide and propafenone
are the most effective agents, apart from amiodarone, in
terminating recent-onset atrial fibrillation (22–24) and in
preventing paroxysmal atrial fibrillation recurrences (25,26).
In ventricular defibrillation, flecainide and encainide in-
creased defibrillation energy requirements (27,28) and con-
flicting data were reported on propafenone in animal studies
(29,30). The use of class 1C agents is usually avoided in
patients with ventricular tachyarrhythmias (31).
Van Gelder et al. (10) evaluated the effects of an IV
loading of flecainide in a randomized placebo-controlled
study performed on patients with long-standing atrial fibril-
lation, who submitted to conventional transthoracic cardio-
version; the authors described a trend toward an increase in
defibrillation energy requirements in drug-treated patients,
who more often required shocks at relatively high energies
(200 or 400 J). In an observational study (32), patients with
chronic atrial fibrillation treated with oral flecainide re-
quired higher energies for successful transthoracic cardio-
version, in comparison with patients treated with class 1A
drugs or with amiodarone, but the success rate of cardio-
version was the same in all the groups.
In the present report, IV flecainide significantly reduced
cardioversion energy requirements: the percent reduction in
mean delivered energy was 50% in paroxysmal atrial fibril-
lation and 21% in chronic persistent atrial fibrillation and
associated reductions in leading-edge voltage were 29% and
12%, respectively. Moreover, in half the patients with
persistent atrial fibrillation resistant to cardioversion at
baseline, conversion to sinus rhythm was achieved after drug
infusion. Energy requirements for atrial cardioversion were
reproducible in the drug-free state, after atrial fibrillation
reinduction, and only after flecainide administration was a
significant reduction in energy requirements compared to
baseline found, thus excluding a potential bias due to lack of
reproducibility.
The favorable effects of IV flecainide on defibrillation
energy requirements were associated with a marked increase
in mean FF intervals, either in HRA or CS (Fig. 5), as a
result of flecainide pharmacodynamic effects (33). A length-
ening of mean FF intervals usually implies a reduction in the
number of circulating wavelets in the atria (34,35), thus
leading to a more organized arrhythmia where interruption
may be easier, even by defibrillation (35). Indeed, even
spontaneous termination of paroxysmal atrial fibrillation in
humans is associated with a lengthening of mean FF
intervals (17). In conscious dogs, lengthening of atrial
fibrillation cycle after administration of a new class 1C drug
(36) was correlated with lengthening of the shortest possible
atrial wavelength, and the antifibrillatory effects of the drug,
measured by these electrophysiological changes, were re-
lated to a reduction of the number of circulating wavelets
(36). Wang et al. (37) demonstrated in a dog model that
flecainide causes organization of atrial fibrillation, reduces
the number of reentry circuits, and may terminate atrial
fibrillation by increasing the wavelength of atrial fibrillation
to the point that the arrhythmia can no longer sustain itself.
Figure 5. Surface ECG recordings (leads aVR and D1) and
intracavitary bipolar recordings (HRA 5 high right atrium; CS 5
coronary sinus) in a patient at baseline (top) and after flecainide IV
infusion (bottom). A lengthening of atrial fibrillation cycle is
evident in either HRA or CS recordings.
Table 3. Effects of IV Flecainide on ECG and Electrophysiological Parameters
Baseline
After IV
Flecainide
p
Value
Mean FF interval HRA (ms) 168 6 24 261 6 35 ,0.001
Mean FF interval CS (ms) 163 6 27 259 6 44 ,0.001
Mean RR interval (ms) 674 6 192 633 6 108 0.236
QRS interval width (ms) 80 6 11 105 6 18 ,0.001
Pause at SR resumption (ms) 994 6 432 1398 6 812 0.015
HRA 5 high right atrium; CS 5 coronary sinus; SR 5 sinus rhythm.
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These effects may explain how flecainide makes electrical
cardioversion of atrial fibrillation easier.
In conventional transthoracic cardioversion of long-
standing atrial fibrillation, Van Gelder et al. (10) found after
IV loading of flecainide a trend toward an increase in
defibrillation energy requirements, but many differences
exist in the design of that study compared to the present one
(parallel study vs. sequential study) and in the methodology
of shock delivery (transthoracic monophasic shocks vs.
biphasic endocardial shocks) and it could be matter of
speculation to consider how the different methodologies
may condition the results.
Bianconi et al. (12), in a randomized controlled study on
the effects of propafenone pretreatment in transthoracic
cardioversion, found that the beneficial effects of
propafenone were associated with transformation of the
atrial fibrillation pattern into a flutter-like ECG pattern.
This finding indeed is consistent with our observation of a
marked lengthening of mean FF intervals after flecainide,
but in our view analyses of surface ECGs have major
limitations in studying the electrophysiological pattern of
atrial fibrillation and its dynamic changes (17,38).
The electrophysiological effects of flecainide at the atrial
level include a marked slowing of conduction and a rate-
dependent increase in refractoriness, which is therefore
particularly enhanced during atrial fibrillation (37,39). Our
study did not allow us to determine which of these changes
are responsible for obtaining a reduction in defibrillation
energy requirements, but the final result is clearly related to
a pharmacological effect, as demonstrated by QRS widening
and attainment of serum concentrations within the thera-
peutic range (19).
Implications in clinical practice. According to the results
of the present study, intravenous administration of flecain-
ide may have several useful indications in patients with
chronic persistent atrial fibrillation treated with electrical
cardioversion. The first indication is related to the ability of
this drug to increase the likelihood of restoring sinus rhythm
(half of the nonresponders at baseline were converted after
flecainide in this study) and this may be of great importance
in chronic persistent atrial fibrillation of long duration,
provided that patients with left ventricular dysfunction are
excluded. As reported in the literature, transvenous endo-
cardial cardioversion may be successful in patients with
previous ineffective transthoracic cardioversion (6,7); how-
ever, cardioversion efficacy is only 70% in chronic persistent
atrial fibrillation if a maximal output of 400 V is delivered
(3). Therefore, in patients with unsuccessful transvenous
cardioversion, a possible method by which to restore sinus
rhythm is via a pharmacological effect on the substrate.
Antiarrhythmic drugs like flecainide may be indicated for
preventing early recurrences after electrical cardioversion,
which have been reported in 7% to 30% of the cases
(8,10,40). Flecainide administration may be a good choice
in this situation because, according to the results of the
present study, this drug, when administered intravenously,
has a favorable effect on defibrillation energy requirements,
and the overall safety profile is favorable.
A reduction in atrial defibrillation threshold may be
helpful in patients who are candidates for an implantable
atrial defibrillator (2,3,41) but in whom defibrillation
threshold is nearly the maximum output of the device. In
these cases flecainide may be an optimal drug because of the
ability to prevent atrial fibrillation recurrences (25), thus
limiting the device’s need to deliver therapy, coupled with
the ability to reduce defibrillation energy requirements.
However, a prospective study confirming the positive effects
of flecainide on defibrillation energies even during long-
term oral administration is required.
One of the issues associated with transvenous cardiover-
sion is shock-induced discomfort (2,3,7,41,42), which is
unpredictable and shows wide intersubject variability (42).
Flecainide, by reducing defibrillation energy requirements
and the score of shock-related discomfort, may have a
substantial positive impact on patients’ ability to tolerate
internal atrial cardioversion, performed during electrophys-
iological study or by an implanted atrial defibrillator, with a
positive effect on patients’ acceptance of this therapy
(2,41,42). The positive effects of flecainide on shock-
induced discomfort do not seem to be biased by the number
of shocks delivered in sequence; indeed, if a series of shocks
lowers the patient’s tolerability of the shocks, this bias will
be against flecainide, thus enhancing the strength of our
findings. Nevertheless, a prospective trial is required for
evaluating, in a prospective, controlled manner, the impact
of flecainide treatment on these issues.
Risk-benefit ratio. A positive risk-benefit ratio is required
for antiarrhythmic drugs (43) and according to our experi-
ence, acute IV administration of flecainide, under ECG and
blood pressure monitoring, did not cause ventricular proar-
rhythmic effects or hemodynamic deterioration. Two pa-
tients had periods of transient bradycardia after successful
cardioversion requiring temporary pacing, at baseline and
after flecainide, and mean pause after cardioversion was
longer following flecainide, even though no complications
occurred. Sinus pauses or sinus bradycardia may occur at
spontaneous sinus rhythm resumption after a period of atrial
fibrillation (44) and may be increased in duration when
pharmacological cardioversion is performed with flecainide
(22) or when transthoracic electrical cardioversion is per-
formed during oral flecainide (32) or oral propafenone
treatment (12). In clinical practice, the ability to conduct
temporary pacing is required when cardioversion is per-
formed, especially after acute drug administration.
Study limitations. Evaluation of defibrillation energy re-
quirements in humans implies a different approach in
comparison to animal studies where curves of response can
be obtained using multiple sequences of atrial fibrillation
inductions followed by shock delivery (4,5,20,21). Indeed,
for limiting the number of delivered shocks, studies in
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humans have typically employed a step-up protocol
(2,3,7,42,45,46). This technique implies some obvious ap-
proximation and some potential problems of reproducibility.
Moreover evaluation of the effects of flecainide on defibril-
lation energy requirements in patients with chronic persis-
tent atrial fibrillation requires a first cardioversion at base-
line and a subsequent cardioversion, after flecainide
administration, on a reinduced atrial fibrillation. Because of
the potential bias of comparing cardioversion of a long-
standing atrial fibrillation with a reinduced atrial fibrillation,
we analyzed in 10 patients energy requirements at baseline,
after atrial fibrillation reinduction in a drug-free condition
and after flecainide. The lack of significant differences in
defibrillation energy requirements in sequential cardiover-
sions performed in a drug-free condition, coupled with
statistical evidence of favorable effects of flecainide in this
subgroup of patients, strongly supports our findings of the
positive effects of flecainide on defibrillation.
In the literature, conflicting data have been reported on
defibrillation energy reproducibility (45,46). In the study by
Lok et al. (45) atrial defibrillation threshold was reproduc-
ible if shocks were delivered within 2 min, whereas an
increase in defibrillation threshold was found if shocks were
delivered after a pause of 20 min. Conversely, in the study
by Santini et al. (46) lower defibrillation thresholds were
found for the second cardioversion sequence.
According to our protocol, after IV flecainide adminis-
tration, cardioversion sequence began at 80 V under previ-
ous effective shocks; therefore, it can be argued that the
beneficial effects on defibrillation energy requirements can
be underestimated in some cases, because the maximum
detectable reduction was 80 V.
Conclusions. Intravenous flecainide has favorable effects
when used during low-energy internal atrial cardioversion
because it lowers defibrillation energy requirements for
patients with either chronic persistent atrial fibrillation or
paroxysmal atrial fibrillation and secondarily lowers shock-
induced discomfort. Moreover, flecainide increases the pro-
cedure success rate in chronic persistent atrial fibrillation.
This effect on defibrillation energy requirements might be
associated with a marked prolongation of atrial fibrillation
mean cycle. The employment of this drug under ECG and
blood pressure monitoring proved to be safe during cardio-
version, without any ventricular proarrhythmia.
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